The hospital has become the first in the Middle East and North Africa to offer a food intolerance test that uses endomicroscopy. The technique lets doctors see how cells in the small intestine respond to specific foods in real time. The service has been approved by the Department of Health, Abu Dhabi, which matters in a market where new clinical procedures face close regulatory scrutiny.

How does it work?

The test builds on a standard endoscopy. A specialist passes a flexible scope into the upper digestive tract, and a tiny microscope probe is used to magnify the lining of the small intestine to the cellular level. The patient is then exposed to suspected trigger foods, and the doctor watches the tissue for signs of reaction, such as gaps opening between cells or fluid leaking into the gut wall.

That is a different approach from the blood tests and elimination diets most clinics rely on. Those methods measure indirect signals or depend on a patient’s own memory of symptoms. Endomicroscopy observes the tissue itself. The result is a visible, patient-specific answer rather than a statistical hint.

Why does it matter?

Digestive complaints are common across the Gulf, and so is frustration with diagnosis. Patients often move between clinics for months, trying one diet after another. A test that links a named food to a visible cellular response could shorten that journey and spare people from needlessly restrictive eating.

There is a caution, though. The procedure is invasive compared with a blood draw, and it requires specialist equipment and training. It will suit patients with persistent, unexplained symptoms rather than anyone with mild bloating after a heavy meal. Clinicians will need to be clear about who should be referred.

The context

The launch fits a wider pattern in the UAE. Abu Dhabi has spent years positioning itself as a centre for advanced, personalised medicine, with genomics programmes, AI-assisted diagnostics and international hospital partnerships all part of that effort. Saudi Arabia’s Vision 2030 health goals point in the same direction: bring complex, specialised care closer to home and reduce the number of patients travelling abroad for it.

Offering a regional first also strengthens the case for medical tourism. Patients from neighbouring GCC states and beyond may now find a diagnostic option in Abu Dhabi that previously meant a trip to Europe or North America.

The real test will be evidence. Hospitals, insurers and regulators will want outcome data showing that patients who follow the results actually feel better. If that data arrives, endomicroscopy could become a standard tool for stubborn digestive cases. If not, it remains an impressive image. For now, Abu Dhabi has the technology, and the region will be watching what it shows.

The post Cleveland Clinic Abu Dhabi lets doctors watch the gut react to food appeared first on DH Arab.

The Memorandum of Understanding sets a framework for cooperation across four areas: specialised clinical services, physician expertise, medical innovation and professional development. It is a framework, not a finished programme. The detailed terms, timelines and financial arrangements have not been made public, so the real test lies in what the two organisations build on it.

How will it work?

The MoU is built around the four areas of cooperation, and each one points to a practical benefit.

• Specialised clinical services: patients at either site may gain easier access to services the other provider is better equipped to deliver.
• Physician expertise: doctors can share knowledge and experience across both organisations.
• Medical innovation: the partners can explore new approaches to care together.
• Professional development: training and learning opportunities can be offered to clinical teams on both sides.

In practice, this kind of agreement usually starts with referral pathways and joint training sessions, then grows if the early results are good. That is a reasonable expectation here, though neither party has confirmed a rollout schedule.

Why does it matter?

For patients, the gain is continuity. A clinic in a residential community such as Khalifa City can be the first point of contact, while a hospital provides deeper specialist capacity. When the two work under a formal arrangement, the handover between them should be smoother and faster.

For clinicians, the value is in the exchange. Smaller facilities often struggle to keep teams current across every specialty. Shared development programmes help close that gap without every provider building everything alone.

And for the sector, it is a signal. Private providers in Abu Dhabi are choosing collaboration over going it alone, which is what policymakers have been encouraging for years.

The context

The setting matters. The Future Health Summit is one of several forums in the UAE where providers, regulators and investors line up announcements around the national health agenda. Abu Dhabi has pushed hard to raise care standards, widen specialist access and bring innovation into everyday practice, and the Department of Health has made integrated care a clear priority.

The same thinking runs across the GCC. Saudi Arabia’s Vision 2030 health transformation programme rests on connected, patient-centred care, and other member states are moving in a similar direction. Partnerships like this one are how that policy reaches the ground, one agreement and one referral at a time.

Still, an MoU is an intention, not an outcome. The measure of success will be simple: shorter waits, better coordination and trained staff who stay. If Reem Hospital and Yas Clinic Khalifa City can show that, others in the emirate will likely follow.

The post Reem Hospital and Yas Clinic Khalifa City join forces in Abu Dhabi appeared first on DH Arab.

The treatment under study is MB-111, an investigational therapy for patients with severely elevated blood lipid levels. The source announcement was brief, so some trial details, including enrolment numbers, timelines and the exact target gene, have not yet been made public. What is clear is the milestone itself: the country’s first trial of this kind.

How will it work?

LNPs are tiny fat-based capsules that carry genetic instructions into cells. Many people know them from mRNA COVID-19 vaccines. Here, the same delivery method is used to carry gene-editing tools to the liver, where cholesterol and other blood fats are regulated.

The idea is simple to state and hard to execute. Instead of asking patients to take daily pills or regular injections for life, a gene-editing therapy aims to change how the body handles lipids at the source. In principle, one treatment could produce a lasting effect. Whether MB-111 does so is exactly what a clinical trial must establish.

IROS will manage the study locally. That means recruiting eligible patients, coordinating sites, and handling regulatory and data requirements. Mammoth Biosciences brings the therapy and the editing technology behind it.

Why does it matter?

Severely raised blood lipids are a serious problem in the Gulf. Cardiovascular disease is a leading cause of death across the GCC, and high rates of diabetes and obesity add to the risk. Patients with inherited or treatment-resistant lipid disorders often cannot reach safe levels with standard drugs alone.

But the significance goes beyond one drug. Running an early gene-editing trial inside the UAE means local clinicians gain direct experience with the therapy, and local patients get access to research that would otherwise happen abroad. It also tests whether regulators, hospitals and laboratories can handle the safety monitoring these studies demand.

That capability is hard to build and easy to lose. A first trial creates a template for the second and third.

The context

M42 was created to turn Abu Dhabi into a hub for genomics, precision medicine and clinical research. The Emirati Genome Programme, which has sequenced hundreds of thousands of people, gives that ambition a data foundation. A gene-editing trial is the logical next step: a place where genomic knowledge meets treatment.

The move also fits wider regional strategy. Saudi Arabia’s Vision 2030 prioritises life sciences and local clinical research, and the UAE has spent years courting global biotech firms with faster approvals and strong hospital networks. Partnerships like this one are how those policies become real studies with real patients.

Challenges remain. Gene-editing therapies are expensive, long-term safety data is still limited, and early-phase results can disappoint. Still, the Gulf is no longer waiting for these treatments to arrive. It is helping test them. For healthcare leaders in the region, that shift deserves close attention.

The post The UAE is about to run its first gene-editing trial for a cholesterol disorder appeared first on DH Arab.

The two companies have signed a partnership to explore sustainability, digital innovation and operational improvements across PureHealth’s facilities and infrastructure. The announcement is an agreement to explore, not a finished programme. Still, the direction is clear, and it matters for anyone running a health system in the Gulf.

How will it work?

Schneider Electric will give PureHealth access to its EcoStruxure Resource Advisor platform, a tool that gathers energy, water and emissions data in one place. The source material is cut off after that point, so further details of the rollout are not yet public. But the logic of such a tool is well established.

Facilities teams typically hold data in separate systems, from chillers and lighting to power supply and water use. Bringing it together lets managers spot waste, compare sites and report progress against targets. The wider collaboration will look at digital tools and infrastructure upgrades across PureHealth’s hospitals and clinics.

Expect the early work to focus on measurement. You can’t cut what you can’t see, and many healthcare groups still lack a clear, consolidated picture of their own consumption.

Why does it matter?

Healthcare is a heavy emitter. Operating theatres, imaging suites, laboratories and strict air quality requirements all demand constant power and cooling, and in the Gulf climate the cooling load alone is substantial. Every dirham saved on utilities is a dirham that can go back into patient care.

There is also a reputational and regulatory angle. Hospital operators across the region are being asked to show progress on net zero, and the UAE has set a 2050 target. A group the size of PureHealth, with a large portfolio of hospitals, clinics and diagnostics, can move the national numbers on its own.

And the digital side is not a side issue. Operational data helps leaders plan maintenance, reduce downtime and keep critical equipment running. In a hospital, that is a clinical safety matter as much as a financial one.

The context

PureHealth was created to consolidate Abu Dhabi’s public and private healthcare assets under one umbrella, and it has grown quickly through acquisitions and partnerships. Scale brings a difficult side effect: dozens of buildings with different ages, systems and standards. Standardising how they are monitored is a practical first step.

The deal also fits a wider GCC pattern. Saudi Arabia’s Vision 2030 pushes hospitals toward efficiency and private sector participation, while the UAE is tying health strategy to its Net Zero 2050 commitment and national digital agenda. Governments want healthcare that is both higher quality and cheaper to run.

So the real test is delivery. Partnerships to explore are common in this region. Those that publish baselines, set targets and report results are rarer, and they are the ones that will change how Gulf hospitals are built and operated.

The post Schneider Electric and PureHealth bet that greener hospitals will also run better appeared first on DH Arab.

Imperial College London Diabetes & Endocrine Centre (ICLDEC), part of M42, and Rochester Institute of Technology Dubai (RIT Dubai) have signed a Memorandum of Understanding (MoU). The goal is to equip healthcare professionals with the data and technology skills that clinical practice and research now require.

How will it work?

The MoU is a framework, not yet a finished curriculum, so details will emerge as the two institutions begin working together. The logic is clear, though. ICLDEC brings clinical and research depth in diabetes and endocrinology, along with access to the patient realities that M42’s network sees every day. RIT Dubai brings technical teaching strength in computing, data science and applied technology.

Together, they are expected to build training that links the two worlds. That could include:

• Short courses in data analysis and digital tools for working clinicians
• Joint research projects that pair medical and technical expertise
• Academic exchange between teams at both institutions

The practical aim is simple. A clinician should leave with skills they can use on Monday morning, not just theory.

Why does it matter?

Diabetes is the obvious test case. The UAE has one of the higher diabetes burdens in the world, and the condition generates enormous amounts of data, from glucose monitors to genomic records. That information only helps patients if clinicians can interpret it with confidence.

But there is a wider issue. Hospitals across the Gulf are buying artificial intelligence tools, building digital records and launching remote monitoring programs. Technology is arriving faster than the workforce is being prepared to use it. And a tool in the hands of an untrained user is a risk, not an asset.

So the real value here is human capital. Investing in people who can work at the point where medicine and technology meet is arguably a better bet than another software purchase.

The context

This fits a clear regional pattern. Abu Dhabi has made genomics, precision medicine and digital health central to its health strategy, and M42 is one of the main vehicles for that ambition. Dubai, meanwhile, has pushed hard on digital health records and smart services, and RIT Dubai sits within that technology-minded academic scene.

Across the GCC, national plans including Saudi Vision 2030 share the same priorities: preventive care, digital transformation and a skilled local workforce. Each depends on clinicians who are comfortable with data. Policy documents can set the direction, but training programs decide whether anyone arrives.

Still, an MoU is a starting point. The test will come in the months ahead: how many professionals are trained, how quickly programs launch and whether the skills change daily practice. If the partnership delivers, it could become a template for other health systems in the region. If it stays on paper, it will be one more agreement among many.

The post Doctors are learning to code, and Abu Dhabi wants to lead the lesson appeared first on DH Arab.

The study is called CARE-UAE. It ran at Cleveland Clinic Abu Dhabi and enrolled 25 patients between October 15 and 23, 2026. All were already scheduled for screening, diagnostic or surveillance colonoscopy. The work is a partnership with US firm Neptune Medical and has the backing of the Department of Health, Abu Dhabi (DoH). It was highlighted at the Abu Dhabi Future Health Summit 2026. Organisers describe it as one of the first studies of its kind in the emirate, and it is the first clinical evaluation of Neptune’s Triton Robotic Endoscopy System in the Middle East.

Twenty-five patients is a small number. Nobody should read results into it yet. But the point of an early study like this is to test whether the technology behaves well in a new clinical setting, and to start building local evidence.

How did it work?

CARE-UAE has two parts, and they are separate.

The first part assesses the Triton system’s navigation and shape-tracking features. These are designed to help clinicians guide the endoscope through the colon. A key test is whether the device reaches the caecum, the start of the large intestine. Reaching it is the standard anatomical marker that an examination is complete.

The second part collects data using an AI-assisted polyp detection platform. This platform is not part of Triton. Neptune plans to fold similar capabilities into future versions of the system, so the data will inform that work.

Dr. John Rodriguez, Chief of the Digestive Disease Institute at Cleveland Clinic Abu Dhabi, said the technology should help clinicians recognise and remove polyps that standard colonoscopy can easily miss. That is a hope for now, not a finding.

Why does it matter?

Early detection is the whole game in colorectal cancer. Precancerous polyps can be removed before they turn dangerous, so a missed polyp is a missed chance. Any tool that improves detection or makes the procedure more reliable could change outcomes at scale.

Neptune CEO Alex Tilson pointed to the company’s earlier CARE 1 and CARE 2 studies and its recent FDA clearance as milestones. He said real-world data on AI-assisted detection is central to the next generation of Triton.

The regulatory message is just as important. Dr. Asma Ibrahim Al Mannaei of the DoH said emerging technologies must be evaluated rigorously, with patient safety at the centre. Abu Dhabi wants to contribute to international research while building evidence in its own clinical setting.

The context

This fits a clear pattern across the Gulf. The UAE has positioned itself as a leader in AI, and Abu Dhabi has made health research and life sciences a policy priority. The summit’s theme, ‘To Sense Is to Predict’, reflects the same logic: earlier insight, earlier action. Its four impact areas included Digital Health and AI and Investment in Life Sciences. The wider GCC, under national strategies such as Saudi Vision 2030, is pursuing similar goals in digital health and preventive care.

Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi, said the ambition is to create solutions in Abu Dhabi that set standards of care globally. That is a big claim for a 25-patient study. Still, hosting early clinical evaluations is how a health system earns a seat in medtech development, rather than simply buying the result later.

The real test will come with larger studies and hard data on detection rates. For now, CARE-UAE shows that Abu Dhabi has the regulatory framework, clinical expertise and appetite to run such trials. Its findings will add to the evidence on robotic endoscopy and guide further development.

The post A robot, an AI and 25 patients: Abu Dhabi tests the next colonoscopy appeared first on DH Arab.

The initial programmes cover four areas: neuroscience, cardiovascular disease, oncology and immunology. These are not niche choices. Heart disease, cancer and neurological conditions weigh heavily on health systems across the GCC, and immunology is a growing concern as autoimmune and inflammatory conditions are diagnosed more often.

How does it work?

The hub links Novartis’s global Phase 3 research with Abu Dhabi’s hospitals, clinicians and regulatory system. Instead of treating the emirate as a late stop for approved drugs, the model brings patients into studies while those studies are still running. The same protocols apply as anywhere else in the world, which is what makes the data usable for international approval.

The DoH acts as both regulator and convener. That matters. Trial delays often come from slow approvals, fragmented ethics review and difficulty recruiting patients. A single authority that sets the rules and backs the programme can shorten each of those steps. Whether it does so in practice is the thing to watch.

Why does it matter?

For patients, the benefit is direct. Participants may gain early access to therapies years before they are widely available, along with close monitoring by specialist teams. For clinicians, running global trials builds skills and credibility that stay in the system long after a study closes.

There is an economic argument too. Clinical research brings investment, skilled jobs and links with international pharmaceutical companies. And there is a scientific one. Gulf populations are underrepresented in trial data, so treatments are often tested on people whose genetics, diets and disease patterns differ from those of the region. Local participation helps fix that.

The context

The hub fits neatly into Abu Dhabi’s long-running effort to build a life sciences sector, and into the wider UAE strategy of moving from importing healthcare to producing knowledge. Saudi Arabia’s Vision 2030 sets similar goals, with research capacity and local health industries high on the agenda. Across the GCC, governments are competing, and cooperating, to become credible research destinations.

But credibility has to be earned. Trial sponsors look for fast enrolment, clean data and reliable regulators. Abu Dhabi has the funding and the infrastructure. It now needs volume, and a steady record of delivery.

If the Novartis programmes meet those tests, other companies are likely to follow. That would turn a single partnership into a real regional research base, and give Gulf patients a place in the evidence that shapes their own treatment.

The post Abu Dhabi wants to be where the world’s drug trials happen appeared first on DH Arab.

The agreement centres on professional education, scientific exchange and research. The source material is brief on specifics, so the details of individual programmes have yet to be made public. But the direction is clear: build clinical expertise at home and connect local practitioners with global science.

How will it work?

An MoU is a framework, not a funding announcement. It sets out where two parties intend to cooperate, and the work follows. Here, the collaboration is built around three areas:

• Professional education for clinicians and specialists working in fertility and reproductive health
• Scientific exchange between Abu Dhabi’s medical community and Merck’s international research network
• Joint research activity to generate evidence relevant to the region

DoH will bring its authority as the sector regulator. Merck will bring its scientific and technical depth in reproductive health. Together they can shape training standards and research priorities, and that matters more than any single event or workshop.

Why does it matter?

Infertility is a real public health issue in the Gulf. Rates of lifestyle conditions such as obesity and diabetes, both linked to reproductive health, are high across the GCC. Many couples also seek treatment later in life. And demand for assisted reproduction keeps growing.

So the quality of local expertise counts. Patients who can find advanced, evidence-based care in Abu Dhabi are less likely to travel abroad for it. That keeps clinical talent, spending and data inside the Emirate. It also gives the regulator a stronger hand in setting consistent standards.

There is a demographic angle too. Several Gulf governments have made family growth and population health part of their long-term planning, and fertility services sit squarely within that thinking.

The context

This deal fits a pattern. Abu Dhabi has spent years positioning itself as a hub for life sciences, with genomics, precision medicine and clinical research all receiving sustained policy attention. The Emirati Genome Programme and the Healthcare Sector strategy from DoH point the same way: move from treating illness to anticipating it, and base decisions on local data.

Across the GCC, the same logic runs through Saudi Vision 2030 and its health sector transformation programme, which also stresses localised expertise, private sector partnership and better outcomes. Reproductive health is a natural next step, because it combines clinical need with research potential and economic value.

Still, an MoU is only a beginning. The test will be whether it produces trained specialists, published research and measurable improvements in patient care. Health leaders should watch for concrete programme launches over the coming months. If they arrive, Abu Dhabi will have shown how a regulator can work with industry to build capability, not just oversee it.

The post Abu Dhabi bets on fertility science with a new Merck partnership appeared first on DH Arab.

What’s the news?

Malaffi, the Emirate’s health information exchange, has reached close to 90% adoption of Logical Observation Identifiers Names and Codes (LOINC), the international standard for naming laboratory tests. The Department of Health, Abu Dhabi (DoH) regulates the sector and set the mandate. Malaffi was established in 2019 with M42’s Abu Dhabi Health Data Services (ADHDS), and it links more than 3,000 public and private facilities.

The method was practical. Each provider’s test catalogue was mapped to LOINC codes and built into its laboratory information system at source, so results were generated in the standard from the start. Real-time validation rules flagged unmapped or wrongly coded tests. Quality dashboards let both the Malaffi informatics team and providers track coverage, consistency and drift, especially as new tests and panels appeared. DoH also has monitoring tools to enforce the mandate when needed.

Why does it matter?

A connected system gives you access to information. An interoperable one gives you information that means the same thing everywhere. Without shared codes, a haemoglobin result from one laboratory may not line up with the same test from another, and comparing trends or pooling data becomes unreliable.

The benefits reach several groups:

• Clinicians face less ambiguity when reading results from different laboratories, particularly for patients who move between providers.
• Patients get a laboratory history that reads consistently wherever they were treated.
• Regulators can aggregate and analyse results across the whole population to support policy and public health programmes.
• AI developers get cleaner, standards-based data on which to build accurate and reliable models.

That last point is the strategic one. Predictive analytics and precision medicine are only as good as the data beneath them. Poorly coded data produces poor models, however sophisticated the algorithm.

The context

Across the GCC, governments are investing heavily in digital health under national agendas such as Saudi Vision 2030 and the UAE’s own health strategies. Most of that effort has gone into building connections: national records, exchanges, telehealth. Standardisation is the less visible second phase, and it is where many systems will be tested. Few exchanges worldwide have achieved LOINC adoption at this scale.

The Malaffi experience also carries a warning. The project was not treated as a one-off technology rollout. It relied on sustained regulatory governance, cooperation between competing providers, and constant monitoring, because standards drift as medicine changes. Regional health authorities planning their own exchanges should note that the technical mapping is the smaller job. Keeping it accurate year after year is the larger one.

Laboratory data is only one domain, of course. Radiology, medications and diagnoses all need the same discipline. But Abu Dhabi has shown that an entire ecosystem can be brought into line, and that gives the DoH’s ‘Healthier Abu Dhabi’ ambition a firmer data base. The next test is what the emirate builds on it.

The post Malaffi hits 90% LOINC adoption, and Abu Dhabi’s lab data now speaks one language appeared first on DH Arab.

The program is selective. Ten researchers from leading universities and research institutions worldwide were chosen from more than 1,000 applications across over 50 countries. Over six months, they will work across neuroscience, artificial intelligence, neurotechnology and brain health.

Neuratia Labs, which operates between Dubai and Mumbai, is an AI-driven neurotechnology company building research infrastructure and tools for brain-signal analysis and brain health. CliniDataCue specializes in healthcare data infrastructure. It helps organizations source, structure, manage and govern medical data for clinical research and healthcare AI.

How will it work?

CliniDataCue will support the fellowship’s research ecosystem. It will help participating researchers work out what data their projects need and explore potential access to relevant datasets. The announcement gives no detail on which datasets are involved or how access will be granted, so that remains to be seen.

Why does it matter?

Data access is one of the biggest bottlenecks in healthcare AI. Brain research makes it harder still, because neural data is complex and sensitive. Pairing young researchers with a partner focused on governance, not just supply, is a sensible move.

It also matters for the Gulf. The UAE has made digital health and AI central to its health agenda, and Dubai wants to be a base for global health innovation. A fellowship that draws talent from 50 countries and is linked to a Dubai company fits that ambition.

The context

Across the GCC, governments are building national health data frameworks and investing in AI-enabled care. Saudi Arabia’s Vision 2030 and the UAE’s digital health strategies both depend on trustworthy, well-governed data. Without it, AI tools struggle to earn clinical confidence.

Neuratia describes the partnership as part of a wider effort to connect researchers, technology companies and healthcare innovators. The real test will be what the ten fellows produce, and whether the data support makes a visible difference.

More information is available at Neuratia Labs and CliniDataCue.

The post Neuratia Labs picks CliniDataCue to solve the data problem facing its first research fellows appeared first on DH Arab.